Novartis

Novartis phase III trial meets primary endpoint

Friday, July 8, 2011 12:26 PM

Novartis announced phase III trial results that showed more than one-third of patients taking AfinitorR (everolimus) tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC).

More... »

FDA approves Novartis drug to treat pancreatic neuroendocrine tumors

Friday, May 6, 2011 12:34 PM

The FDA has approved the Novartis drug Afinitor(everolimus) for the treatment of advanced pancreatic neuroendocrine tumors. 

More... »

Novartis CEO unveils drug development strategy

Wednesday, May 4, 2011 12:43 PM

During a recent interview with Fortune, Novartis CEO Joe Jimenez explained the company's drug development strategy. He reported that Novartis isn’t targeting blockbuster indications but are more focused on pathways, as reported in Fierce Biotech.

More... »

Sosei, Novartis report NVA237 improves lung function

Tuesday, April 19, 2011 12:31 PM

International biopharmaceutical and drug development company Sosei reports that NVA237, a long-acting muscarinic antagonist (LAMA) being investigated as a once daily treatment for chronic obstructive pulmonary disease (COPD), achieved its primary end point in a phase III study. The drug is licensed to Novartis; the company confirmed results from the first phase III clinical trial with once-daily NVA237 (glycopyrronium bromide) show that it significantly improved lung function while demonstrating a good safety profile in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »

Vanda begins trial for long-acting injectable to treat schizophrenia

Monday, April 11, 2011 12:52 PM

Vanda Pharmaceuticals and Novartis Pharmaceuticals, an affiliate of Vanda's sublicensor Novartis Pharma AG, has initiated a clinical study to evaluate the long-acting injectable (or depot) formulation of Fanapt (iloperidone).  This is a phase I study that will evaluate the safety and pharmacokinetic profiles of two different long-acting formulations of Fanapt in patients with schizophrenia.

More... »

Novartis’ Gilenya reduced the risk of MS disability progression, analysis shows

Monday, April 11, 2011 12:44 PM

A new analysis demonstrated that Novartis' Gilenya (fingolimod) reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology (AAN).

More... »

Novartis to sell Elidel to Meda

Friday, April 8, 2011 10:56 AM

Switzerland-based Novartis will sell the global rights to manufacture and market Elidel skin cream to Meda Pharmaceuticals, based in Sweden, for an upfront payment of $420 million, according to a Bloomberg report.

More... »

SuperGen and Astex to merge

Friday, April 8, 2011 10:47 AM

U.S.-based SuperGen will merge with the U.K.'s Astex Therapeutics in a deal they say will create "a financially strong international oncology company," according to Pharma Times.

More... »

Novartis' hepatitis C treatment shows positive results

Thursday, April 7, 2011 11:38 AM

Novartis' investigational oral agent alisporivir cured almost 50% more previously untreated patients with the most common form of hepatitis C when added to a standard treatment regimen, as reported in phase II data presented at the European Association for the Study of the Liver congress in Berlin.

More... »